Login to Your Account



Portola turns to FDA for antidote to Andexxa CRL

By Michael Fitzhugh
Staff Writer

Thursday, August 18, 2016

An FDA CRL for Portola Pharmaceuticals Inc.'s factor Xa inhibitor antidote, Andexxa, left the company "significantly surprised," said CEO Bill Lis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription